Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 15/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.76 |
| ▸ | USP2 | O75604 | 2/20 | 0.58 |
| ▸ | USP8 | P40818 | 2/20 | 0.58 |
| ▸ | DUSP26 | Q9BV47 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3577815 | 0.93 | PIK3CG (1.00) | PIK3CGPIK3CDUSP2USP8 | |
| SCHEMBL2302991 | 0.87 | PIK3CD (0.82) | PIK3CGPIK3CD | |
| SCHEMBL2303352 | 0.87 | PIK3CD (1.00) | PIK3CGPIK3CD | |
| SCHEMBL21321589 | 0.87 | PIK3CG (0.76) | PIK3CGPIK3CDUSP2DUSP26 | |
| SCHEMBL2302599 | 0.86 | PIK3CD (0.80) | PIK3CGPIK3CD | |
| SCHEMBL3580401 | 0.84 | PIK3CG (1.00) | PIK3CGPIK3CD | |
| SCHEMBL3835583 | 0.83 | PIK3CG (0.84) | PIK3CGDUSP26 | |
| Potassium SCHEMBL3577697 | 0.83 | PIK3CG (0.98) | PIK3CGPIK3CD | |
| SCHEMBL3823005 | 0.82 | PIK3CG (0.74) | PIK3CGPIK3CD | |
| SCHEMBL3582134 | 0.81 | PIK3CG (0.68) | PIK3CGPIK3CDDUSP26 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118076-B1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO SA (CH) | 2019-09-04 | — | — | EP | claimed |
| EP-2118076-B1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO SA (CH) | 2019-09-04 | — | — | EP | disclosed |
| US-8614215-B2 | Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks) | MERCK SERONO SA (CH) | 2013-12-24 | — | — | US | disclosed |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | disclosed |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | disclosed |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | disclosed |
| WO-2008101979-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | PFKP, PDXK, PF4 | PIK3CG 595/4885PIK3CD 703/4885USP2 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.